Current Report Filing (8-k)
May 05 2022 - 04:44PM
Edgar (US Regulatory)
0001583107 false 0001583107 2022-05-05
2022-05-05 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
Current Report Pursuant
to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event Reported):
May 5, 2022
THERAVANCE BIOPHARMA, INC.
(Exact Name of Registrant as Specified in its Charter)
Cayman Islands |
|
001-36033 |
|
98-1226628 |
(State or Other
Jurisdiction of |
|
(Commission File
Number) |
|
(I.R.S. Employer
Identification |
Incorporation) |
|
|
|
Number) |
PO Box 309
Ugland House, South Church Street
George Town, Grand Cayman,
Cayman Islands
KY1-1104
(650)
808-6000
(Addresses, including zip code, and telephone numbers, including
area code, of principal executive offices)
Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the
registrant under any of the following provisions (see General
Instruction A.2. below):
¨ Written communications
pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
¨ Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
¨ Pre-commencement
communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement
communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the
Act:
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which
registered |
Ordinary Share $0.00001 Par Value |
|
TBPH |
|
NASDAQ
Global
Market |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§ 230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§ 240.12b-2 of this
chapter).
Emerging
growth company ¨
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange
Act. ¨
Item 2.02. Results of Operations and Financial
Condition.
On May 5, 2022, Theravance Biopharma, Inc. issued a press release
and is holding a conference call regarding its financial results
for the quarter ended March 31, 2022 and a business update. A copy
of the press release is furnished as Exhibit 99.1 to this Current
Report and a copy of materials that will accompany the call is
furnished as Exhibit 99.2 to this Current Report.
The information in Item 2.02 and in Item 9.01 of this Current
Report on Form 8-K, including Exhibits 99.1 and 99.2, is being
furnished and shall not be deemed “filed” for the purposes of
Section 18 of the Securities Exchange Act of 1934, as amended (the
“Securities Exchange Act of 1934”), or otherwise subject to the
liabilities of that Section, nor shall it be incorporated by
reference in any filing under the Securities Act of 1933, as
amended, or the Securities Exchange Act of 1934, except as
expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
|
THERAVANCE
BIOPHARMA, INC. |
|
|
|
Date: May 5,
2022 |
By: |
/s/ Andrew Hindman
|
|
|
Andrew Hindman |
|
|
Senior Vice President and Chief
Financial Officer |
Theravance Biopharma (NASDAQ:TBPH)
Historical Stock Chart
From Jun 2022 to Jul 2022
Theravance Biopharma (NASDAQ:TBPH)
Historical Stock Chart
From Jul 2021 to Jul 2022